Literature DB >> 9928826

Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology.

M Sadowski1, H M Wisniewski, M Tarnawski, P B Kozlowski, B Lach, J Wegiel.   

Abstract

In Alzheimer's disease (AD), neurofibrillary degeneration of neurons starts in the transentorhinal cortex and spreads in a time-dependent manner to the entorhinal cortex, which provides a major input to the hippocampus--a key structure of the memory system. People with Down's syndrome (DS) develop neurofibrillary changes more than 30 years earlier than those with sporadic AD. To characterize AD-related pathology in the entorhinal cortex in DS, we examined seven subjects with DS of 60-74 years of age who died in the end stage of AD, and four age-matched control subjects. The volume of the entorhinal cortex in brains of subjects with DS was 42% less than that in control cases; however, the total number of neurons free of neurofibrillary changes was reduced in DS by 90%: from 9,619,000 +/- 914,000 (mean +/- standard deviation) to 932,000 +/- 504,000. The presence of 2,488,000 +/- 544,000 neurofibrillary tangles in the entorhinal cortex of people with DS, the prevalence of end-stage tangles, and the significant negative correlation between the total number of intact neurons and the percentage of neurons with neurofibrillary changes indicate that neurofibrillary degeneration is a major cause of neuronal loss in the entorhinal cortex of people with DS. The relatively low amyloid load (7 +/- 1%) and lack of correlation between the amyloid load and the volumetric or neuronal loss suggest that the contribution of beta-amyloid to neuronal loss in the entorhinal cortex is unsubstantial.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9928826     DOI: 10.1007/s004010050968

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.

Authors:  Jerzy Wegiel; Karol Dowjat; Wojciech Kaczmarski; Izabela Kuchna; Krzysztof Nowicki; Janusz Frackowiak; Bozena Mazur Kolecka; Jarek Wegiel; Wayne P Silverman; Barry Reisberg; Mony Deleon; Thomas Wisniewski; Cheng-Xin Gong; Fei Liu; Tatyana Adayev; Mo-Chou Chen-Hwang; Yu-Wen Hwang
Journal:  Acta Neuropathol       Date:  2008-08-12       Impact factor: 17.088

2.  Alzheimer's Disease in Adults with Down Syndrome.

Authors:  Warren B Zigman; Darlynne A Devenny; Sharon J Krinsky-McHale; Edmund C Jenkins; Tiina K Urv; Jerzy Wegiel; Nicole Schupf; Wayne Silverman
Journal:  Int Rev Res Ment Retard       Date:  2008-01-01

3.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

4.  Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.

Authors:  Jerzy Wegiel; Wojciech Kaczmarski; Madhabi Barua; Izabela Kuchna; Krzysztof Nowicki; Kuo-Chiang Wang; Jarek Wegiel; Shuang Ma Yang; Janusz Frackowiak; Bozena Mazur-Kolecka; Wayne P Silverman; Barry Reisberg; Isabel Monteiro; Mony de Leon; Thomas Wisniewski; Arthur Dalton; Florence Lai; Yu-Wen Hwang; Tatyana Adayev; Fei Liu; Khalid Iqbal; Inge-Grundke Iqbal; Cheng-Xin Gong
Journal:  J Neuropathol Exp Neurol       Date:  2011-01       Impact factor: 3.685

Review 5.  The role of DYRK1A in neurodegenerative diseases.

Authors:  Jerzy Wegiel; Cheng-Xin Gong; Yu-Wen Hwang
Journal:  FEBS J       Date:  2010-12-13       Impact factor: 5.542

Review 6.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 7.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

8.  Developmental changes in short-term facilitation are opposite at temporoammonic synapses compared to Schaffer collateral synapses onto CA1 pyramidal cells.

Authors:  Haley E Speed; Lynn E Dobrunz
Journal:  Hippocampus       Date:  2009-02       Impact factor: 3.899

9.  Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.

Authors:  Anne M Fagan; Rachel L Henson; Yan Li; Anna H Boerwinkle; Chengjie Xiong; Randall J Bateman; Alison Goate; Beau M Ances; Eric Doran; Bradley T Christian; Florence Lai; H Diana Rosas; Nicole Schupf; Sharon Krinsky-McHale; Wayne Silverman; Joseph H Lee; William E Klunk; Benjamin L Handen; Ricardo F Allegri; Jasmeer P Chhatwal; Gregory S Day; Neill R Graff-Radford; Mathias Jucker; Johannes Levin; Ralph N Martins; Colin L Masters; Hiroshi Mori; Catherine J Mummery; Yoshiki Niimi; John M Ringman; Stephen Salloway; Peter R Schofield; Mikio Shoji; Ira T Lott
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

10.  Developmental patterns of DR6 in normal human hippocampus and in Down syndrome.

Authors:  Anand Iyer; Jackelien van Scheppingen; Jasper Anink; Ivan Milenkovic; Gabor G Kovács; Eleonora Aronica
Journal:  J Neurodev Disord       Date:  2013-04-24       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.